콘텐츠로 건너뛰기
주식/증권 📈 긍정적

DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026?

요약

DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but competition and reimbursement remain key risks.